Clinical Webinar Series on Pathology
-
You must log in to register
- Member - $200
- Resident Member - Free!
- Allied Staff Member - $200
- Professional Staff Nonmember - $350
- Other Nonmember - $350
- Practice Management CE Subscriber - $200
- CE Subscriber (Clinical & PM) - $200
This series includes two one-hour webinars:
Neoadjuvant Immunotherapy for Oral Cancer on August 12 at 6 p.m. CT
Sinus Pathology and Implications for Oral and Maxillofacial Surgeons on August 19 at 6 p.m. CT
-
Contains 2 Component(s), Includes Credits Includes a Live Web Event on 08/12/2026 at 6:00 PM (CDT)
Neoadjuvant and perioperative immunotherapy plays an ever-evolving role in the treatment of oral cancer. This 60-minute live webinar will break down the latest research surrounding perioperative immunotherapy, including key insights from the landmark KEYNOTE-689 study, and explain how these findings may influence treatment planning before and after surgery. Attendees will gain practical insight into how neoadjuvant immunotherapy may influence surgical planning, treatment sequencing and postoperative decision-making. The session will explore emerging concepts such as checkpoint and TGF-β targeting agents, perioperative pembrolizumab, cancer vaccines and response assessment as well as how to select the patients most likely to benefit from immunotherapy. Code: WCE260812
Neoadjuvant Immunotherapy for Oral Cancer
Neoadjuvant and perioperative immunotherapy plays an ever-evolving role in the treatment of oral cancer. This 60-minute live webinar will break down the latest research surrounding perioperative immunotherapy, including key insights from the landmark KEYNOTE-689 study, and explain how these findings may influence treatment planning before and after surgery. Attendees will gain practical insight into how neoadjuvant immunotherapy may influence surgical planning, treatment sequencing and postoperative decision-making. The session will explore emerging concepts such as checkpoint and TGF-β targeting agents, perioperative pembrolizumab, cancer vaccines and response assessment as well as how to select the patients most likely to benefit from immunotherapy.
Learning Objectives
At the conclusion of this program, participants should be able to:
- Describe the rationale and key clinical implications of perioperative immunotherapy in oral cavity squamous cell carcinoma, including findings from KEYNOTE-689.
- Explain how neoadjuvant immunotherapy may influence surgical planning, pathologic response assessment, adjuvant therapy decisions and long-term outcomes.
- Identify emerging neoadjuvant strategies in oral cancer, including immunoradiotherapy combinations, biomarker-driven treatment personalization and novel immune-based therapeutic platforms.
Cancellation Policy: Registrants will receive a full refund up until the day before the event. No refund will be given on the day of or after the event.
Register for the two-part Clinical Webinar Series on Pathology and save $50 off the original price of $250!
R Bryan Bell, DDS, MD, FRCS(Ed), FACS
Executive Medical Director
Providence Cancer Institute of Oregon
R. Bryan Bell, DDS, MD, FRCS(Ed), FACS, is the Executive Medical Director of Providence Cancer Institute of Oregon, Director and member of the Earle A. Chiles Research Institute and holds the Walter J. Urba Endowed Chair for Cancer Research in Portland, Ore. In these roles, he oversees oncology services and research teams that deliver care to more than 6,000 cancer patients annually in 32 clinics and eight Oregon hospitals.
Dr. Bell has led pioneering research and clinical efforts to integrate immunotherapy into the neoadjuvant setting.
He has served on the National Cancer Institute Head and Neck Steering Committee’s Immunotherapy Clinical Trials Planning Group and the Task Force on Previously Untreated/Locally Advanced (PULA) Disease.
Disclosure(s): Merck (Research Grant, Consultant); Regeneron (Speaker’s Bureau, Consultant); Astrazenaca (Consultant); Johnson & Johnson (Consultant); Adla-Bio (Consultant)
Continuing Education Provider Approval
The American Association of Oral and Maxillofacial Surgeons is an ADA CERP Recognized Provider.ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education.
ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.
The American Association of Oral and Maxillofacial Surgeons designates this activity for 1.0 continuing education credit(s).
AGD - Accepted Program Provider
FAGD/MAGD Credit
11/1/22-12/31/26
Provider ID# 214680The American Association of Oral and Maxillofacial Surgeons (AAOMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Association of Oral and Maxillofacial Surgeons designates this internet-based live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
-
Contains 2 Component(s), Includes Credits Includes a Live Web Event on 08/19/2026 at 6:00 PM (CDT)
Because problems involving the maxillary sinus and dental disease are often connected, OMSs must be able to recognize how one condition can affect the other. This 60-minute live webinar will cover common sinus pathology linked to odontogenic disease by examining real patient cases. A variety of infections and cysts that may result from or impact odontogenic pathology will be covered. Additionally, the webinar will review CT images for specific sinus pathologies and surgical videos demonstrating sinus and odontogenic pathology to better identify these conditions. After attending, participants will be better prepared to recognize sinus-related issues, make informed treatment decisions and provide effective care for patients with both dental and sinus conditions. Code: WCE260819
Sinus Pathology and Implications for Oral and Maxillofacial Surgeons
Because problems involving the maxillary sinus and dental disease are often connected, OMSs must be able to recognize how one condition can affect the other. This 60-minute live webinar will cover common sinus pathology linked to odontogenic disease by examining real patient cases. A variety of infections and cysts that may result from or impact odontogenic pathology will be covered. Additionally, the webinar will review CT images for specific sinus pathologies and surgical videos demonstrating sinus and odontogenic pathology to better identify these conditions. After attending, participants will be better prepared to recognize sinus-related issues, make informed treatment decisions and provide effective care for patients with both dental and sinus conditions.
Learning Objectives
At the conclusion of this program, participants should be able to:
- Identify common pathologic findings using CT in the maxillary sinus.
- Understand the relationship between dental and sinus infections.
- Discuss management of post-implant sinus infections.
- Review opportunities to treat maxillary odontogenic cysts through a transnasal, endoscopic approach.
Cancellation Policy: Registrants will receive a full refund up until the day before the event. No refund will be given on the day of or after the event.
Register for the two-part Clinical Webinar Series on Pathology and save $50 off the original price of $250!
Steven D. Pletcher, MD
Professor of Clinical Otolaryngology; Residency Director
University of California San Francisco
Steven D. Pletcher, MD, is a Professor of Clinical Otolaryngology and Director of the Residency Program in the Department of Otolaryngology – Head and Neck Surgery (OHNS) at the University of California, San Francisco (UCSF). Dr. Pletcher completed his OHNS residency at UCSF, followed by a rhinology fellowship from the Massachusetts Eye and Ear Infirmary in Boston.
Dr. Pletcher’s primary research interests focus on investigation of the role of microbes and host immune response in sinonasal inflammatory disease. He also has specific interests in advancing treatment of sinus disease for adult patients with cystic fibrosis, process improvement in graduate medical education and bettering surgical techniques for chronic sinusitis and refractory epistaxis.Disclosure(s): No financial relationships to disclose
Continuing Education Provider Approval
The American Association of Oral and Maxillofacial Surgeons is an ADA CERP Recognized Provider.ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education.
ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.
The American Association of Oral and Maxillofacial Surgeons designates this activity for 1.0 continuing education credit(s).
AGD - Accepted Program Provider
FAGD/MAGD Credit
11/1/22-12/31/26
Provider ID# 214680The American Association of Oral and Maxillofacial Surgeons (AAOMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Association of Oral and Maxillofacial Surgeons designates this internet-based live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
